BAGNEUX, France, April 28, 2015 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that it has been selected by EnterNext, part of the Euronext exchange, to become a member of the Tech 40 Index tier.
Based on quantitative and qualitative criteria, this Euronext label is awarded on a yearly basis to the top 40 technology companies listed on the SME's* tier of the Euronext exchange.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com.
|DBV Technologies Contacts|
| Nathalie Donne |
Director, Corporate Communication & Business Development
Tél. : +33(0)1 55 42 78 72
VP Finance, US Investor Relations & Strategy
Tél. : +1 917-346-3447
|DBV Technologies Media Contacts|
| Marion Janic |
Rooney & Associates
Tél. : +1-212-223-4017
Tech 40 Label http://hugin.info/156437/R/1915456/684672.pdf